# Rubric Capital Management LP

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1687509. Source: https://holderbook.com/funds/1687509-rubric-capital-management-lp/

- Reported value: $10.9B
- Positions: 87
- Weight of the ten largest: 46.4%
- Filed: 2026-08-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| TALEN ENERGY CORP | [TLN](https://holderbook.com/stocks/TLN/) | $1.4B | 3,602,171 | 12.7% | 8 |
| FTAI AVIATION LTD | [FTAI](https://holderbook.com/stocks/FTAI/) | $811.6M | 3,000,000 | 7.4% | 6 |
| VIATRIS INC | [VTRS](https://holderbook.com/stocks/VTRS/) | $542.6M | 34,168,743 | 5.0% | 5 |
| TEVA PHARMACEUTICAL INDS LTD | [TEVA](https://holderbook.com/stocks/TEVA/) | $527.7M | 15,575,000 | 4.8% | 14 |
| GOLAR LNG LTD | [GLNG](https://holderbook.com/stocks/GLNG/) | $457.5M | 9,178,978 | 4.2% | 21 |
| VISTRA CORP | [VST](https://holderbook.com/stocks/VST/) | $284.7M | 1,794,953 | 2.6% | 3 |
| TRANSALTA CORP | [TAC](https://holderbook.com/stocks/TAC/) | $279.8M | 20,232,011 | 2.6% | 22 |
| FLUOR CORP | [FLR](https://holderbook.com/stocks/FLR/) | $262.9M | 5,017,248 | 2.4% | 1 |
| KINIKSA PHARMACEUTICALS INTL | [KNSA](https://holderbook.com/stocks/KNSA/) | $255.8M | 3,999,800 | 2.3% | 9 |
| BGC GROUP INC | [BGC](https://holderbook.com/stocks/BGC/) | $254.4M | 23,800,000 | 2.3% | 12 |
| ZOOM COMMUNICATIONS INC | [ZM](https://holderbook.com/stocks/ZM/) | $238.7M | 2,766,009 | 2.2% | 2 |
| GILDAN ACTIVEWEAR INC | [GIL](https://holderbook.com/stocks/GIL/) | $232.2M | 4,500,000 | 2.1% | 4 |
| ARCUTIS BIOTHERAPEUTICS INC | [ARQT](https://holderbook.com/stocks/ARQT/) | $216.9M | 8,271,577 | 2.0% | 17 |
| AMAZON COM INC | [AMZN](https://holderbook.com/stocks/AMZN/) | $214.5M | 900,000 | 2.0% | 1 |
| ROIVANT SCIENCES LTD | [ROIV](https://holderbook.com/stocks/ROIV/) | $212.3M | 6,000,000 | 1.9% | 15 |
| ZYMEWORKS INC | [ZYME](https://holderbook.com/stocks/ZYME/) | $183.0M | 7,000,000 | 1.7% | 15 |
| AMCOR PLC | [AMCR](https://holderbook.com/stocks/AMCR/) | $180.4M | 4,162,030 | 1.7% | 2 |
| CIMPRESS PLC | [CMPR](https://holderbook.com/stocks/CMPR/) | $178.0M | 1,750,000 | 1.6% | 5 |
| AMNEAL PHARMACEUTICALS INC | [AMRX](https://holderbook.com/stocks/AMRX/) | $176.0M | 10,168,660 | 1.6% | 13 |
| NURIX THERAPEUTICS INC | [NRIX](https://holderbook.com/stocks/NRIX/) | $175.3M | 7,227,778 | 1.6% | 3 |
| MERCURY GENL CORP NEW | [MCY](https://holderbook.com/stocks/MCY/) | $164.3M | 1,541,440 | 1.5% | 6 |
| PENNYMAC FINL SVCS INC NEW | [PFSI](https://holderbook.com/stocks/PFSI/) | $148.1M | 1,700,000 | 1.4% | 2 |
| INTEGRA LIFESCIENCES HLDGS C | [IART](https://holderbook.com/stocks/IART/) | $139.3M | 7,753,934 | 1.3% | 8 |
| DELEK US HLDGS INC NEW | [DK](https://holderbook.com/stocks/DK/) | $136.5M | 2,687,449 | 1.3% | 8 |
| LIBERTY GLOBAL LTD | [LBTYA](https://holderbook.com/stocks/LBTYA/) | $133.6M | 11,752,855 | 1.2% | 11 |
| MEIRAGTX HLDGS PLC | [MGTX](https://holderbook.com/stocks/MGTX/) | $122.9M | 9,100,000 | 1.1% | 6 |
| GEO GROUP INC | [GEO](https://holderbook.com/stocks/GEO/) | $122.1M | 4,131,219 | 1.1% | 6 |
| LIBERTY LATIN AMERICA LTD | [LILAK](https://holderbook.com/stocks/LILAK/) | $121.9M | 15,645,430 | 1.1% | 4 |
| SCHRODINGER INC | [SDGR](https://holderbook.com/stocks/SDGR/) | $104.0M | 6,400,000 | 1.0% | 10 |
| ECOVYST INC | [ECVT](https://holderbook.com/stocks/ECVT/) | $102.2M | 8,211,888 | 0.9% | 5 |
| LIBERTY GLOBAL LTD | [LBTYK](https://holderbook.com/stocks/LBTYK/) | $101.9M | 9,259,361 | 0.9% | 11 |
| COMPASS INC | [COMP](https://holderbook.com/stocks/COMP/) | $101.3M | 8,218,394 | 0.9% | 3 |
| NEWELL BRANDS INC | [NWL](https://holderbook.com/stocks/NWL/) | $98.2M | 16,000,000 | 0.9% | 4 |
| EDGEWELL PERSONAL CARE CO | [EPC](https://holderbook.com/stocks/EPC/) | $95.2M | 3,544,465 | 0.9% | 3 |
| CORECIVIC INC | [CXW](https://holderbook.com/stocks/CXW/) | $86.5M | 2,847,436 | 0.8% | 6 |
| ARDELYX INC | [ARDX](https://holderbook.com/stocks/ARDX/) | $82.6M | 16,202,700 | 0.8% | 2 |
| ENOVIS CORPORATION | [ENOV](https://holderbook.com/stocks/ENOV/) | $80.7M | 3,900,000 | 0.7% | 4 |
| ADMA BIOLOGICS INC | [ADMA](https://holderbook.com/stocks/ADMA/) | $78.2M | 9,339,414 | 0.7% | 2 |
| MANNKIND CORP | [MNKD](https://holderbook.com/stocks/MNKD/) | $76.7M | 18,000,000 | 0.7% | 4 |
| DRIVEN BRANDS HLDGS INC | [DRVN](https://holderbook.com/stocks/DRVN/) | $73.9M | 5,300,613 | 0.7% | 2 |
| OPKO HEALTH INC | [OPK](https://holderbook.com/stocks/OPK/) | $71.7M | 47,791,243 | 0.7% | 10 |
| MISSION PRODUCE INC | [AVO](https://holderbook.com/stocks/AVO/) | $70.5M | 5,981,953 | 0.6% | 2 |
| ADEIA INC | [ADEA](https://holderbook.com/stocks/ADEA/) | $70.0M | 2,126,633 | 0.6% | 15 |
| RENEW ENERGY GLOBAL PLC | [RNW](https://holderbook.com/stocks/RNW/) | $68.8M | 11,000,000 | 0.6% | 18 |
| STRATASYS LTD | [SSYS](https://holderbook.com/stocks/SSYS/) | $68.5M | 8,000,000 | 0.6% | 12 |
| ARS PHARMACEUTICALS INC | [SPRY](https://holderbook.com/stocks/SPRY/) | $68.4M | 8,540,861 | 0.6% | 6 |
| ANDERSONS INC | [ANDE](https://holderbook.com/stocks/ANDE/) | $68.4M | 999,559 | 0.6% | 3 |
| PRIMO BRANDS CORPORATION | [PRMB](https://holderbook.com/stocks/PRMB/) | $65.3M | 2,672,231 | 0.6% | 3 |
| SONOCO PRODS CO | [SON](https://holderbook.com/stocks/SON/) | $64.4M | 1,143,562 | 0.6% | 1 |
| STUBHUB HLDGS INC | [STUB](https://holderbook.com/stocks/STUB/) | $64.3M | 5,000,000 | 0.6% | 1 |
| GALAXY DIGITAL INC. | [GLXY](https://holderbook.com/stocks/GLXY/) | $64.1M | 2,343,169 | 0.6% | 1 |
| VENTURE GLOBAL INC | [VG](https://holderbook.com/stocks/VG/) | $60.2M | 5,410,280 | 0.6% | 2 |
| ESTABLISHMENT LABS HLDGS INC | [ESTA](https://holderbook.com/stocks/ESTA/) | $59.1M | 688,325 | 0.5% | 1 |
| QUIDELORTHO CORP | [QDEL](https://holderbook.com/stocks/QDEL/) | $57.9M | 3,306,281 | 0.5% | 12 |
| ALVOTECH | [ALVO](https://holderbook.com/stocks/ALVO/) | $57.8M | 15,677,093 | 0.5% | 1 |
| TARGET HOSPITALITY CORP | [TH](https://holderbook.com/stocks/TH/) | $52.7M | 2,586,389 | 0.5% | 7 |
| DNOW INC | [DNOW](https://holderbook.com/stocks/DNOW/) | $50.6M | 3,898,635 | 0.5% | 2 |
| PROTHENA CORP PLC | [PRTA](https://holderbook.com/stocks/PRTA/) | $49.0M | 5,000,000 | 0.4% | 4 |
| TREVI THERAPEUTICS INC | [TRVI](https://holderbook.com/stocks/TRVI/) | $46.7M | 2,504,513 | 0.4% | 17 |
| COLLEGIUM PHARMACEUTICAL INC | [COLL](https://holderbook.com/stocks/COLL/) | $46.3M | 1,279,611 | 0.4% | 26 |
| ARBUTUS BIOPHARMA CORP | [ABUS](https://holderbook.com/stocks/ABUS/) | $36.2M | 7,532,937 | 0.3% | 9 |
| VERSIGENT PLC | [VGNT](https://holderbook.com/stocks/VGNT/) | $35.9M | 855,163 | 0.3% | 1 |
| XPERI INC | [XPER](https://holderbook.com/stocks/XPER/) | $34.1M | 4,143,744 | 0.3% | 15 |
| ORTHOFIX MED INC | [OFIX](https://holderbook.com/stocks/OFIX/) | $34.0M | 3,721,715 | 0.3% | 14 |
| TRIPADVISOR INC | [TRIP](https://holderbook.com/stocks/TRIP/) | $33.4M | 2,439,110 | 0.3% | 1 |
| MATIV HOLDINGS INC | [MATV](https://holderbook.com/stocks/MATV/) | $30.1M | 3,982,442 | 0.3% | 16 |
| LIBERTY LATIN AMERICA LTD | [LILA](https://holderbook.com/stocks/LILA/) | $29.6M | 3,777,654 | 0.3% | 4 |
| BIOHAVEN LTD | [BHVN](https://holderbook.com/stocks/BHVN/) | $25.6M | 1,721,493 | 0.2% | 1 |
| VISTANCE NETWORKS INC | [VISN](https://holderbook.com/stocks/VISN/) | $25.6M | 2,000,000 | 0.2% | 2 |
| ANI PHARMACEUTICALS INC | [ANIP](https://holderbook.com/stocks/ANIP/) | $21.4M | 258,131 | 0.2% | 1 |
| UNIQURE NV | [QURE](https://holderbook.com/stocks/QURE/) | $18.8M | 408,581 | 0.2% | 1 |
| HUDSON PACIFIC PROPERTIES IN | [HPP](https://holderbook.com/stocks/HPP/) | $15.5M | 1,019,598 | 0.1% | 1 |
| SEAPORT ENTMT GROUP INC | [SEG](https://holderbook.com/stocks/SEG/) | $15.1M | 568,530 | 0.1% | 8 |
| GDS HLDGS LTD | [GDS](https://holderbook.com/stocks/GDS/) | $14.6M | 485,873 | 0.1% | 1 |
| HERON THERAPEUTICS INC | [HRTX](https://holderbook.com/stocks/HRTX/) | $12.8M | 30,046,828 | 0.1% | 16 |
| PROTO LABS INC | [PRLB](https://holderbook.com/stocks/PRLB/) | $8.9M | 108,692 | 0.1% | 6 |
| GRUPO AEROMEXICO SAB DE CV | [AERO](https://holderbook.com/stocks/AERO/) | $8.4M | 467,129 | 0.1% | 2 |
| OMEROS CORP | [OMER](https://holderbook.com/stocks/OMER/) | $6.2M | 656,874 | 0.1% | 1 |
| EUPRAXIA PHARMACEUTICALS INC | [EPRX](https://holderbook.com/stocks/EPRX/) | $5.7M | 867,424 | 0.1% | 2 |
| EDESA BIOTECH INC | [EDSA](https://holderbook.com/stocks/EDSA/) | $5.4M | 669,500 | 0.0% | 6 |
| MEREO BIOPHARMA GROUP PLC | [MREO](https://holderbook.com/stocks/MREO/) | $4.9M | 15,307,347 | 0.0% | 23 |
| ABEONA THERAPEUTICS INC | [ABEO](https://holderbook.com/stocks/ABEO/) | $3.8M | 608,771 | 0.0% | 1 |
| CARTERS INC | [CRI](https://holderbook.com/stocks/CRI/) | $3.6M | 86,844 | 0.0% | 3 |
| THERAPEUTICSMD INC | [TXMD](https://holderbook.com/stocks/TXMD/) | $2.6M | 1,192,191 | 0.0% | 17 |
| OPKO HEALTH INC | - | $1.9M | 1,250,000 | 0.0% | 6 |
| TETRA TECHNOLOGIES INC DEL | [TTI](https://holderbook.com/stocks/TTI/) | $1.7M | 150,000 | 0.0% | 1 |
| SERVICE PPTYS TR | [SVC](https://holderbook.com/stocks/SVC/) | $1.5M | 900,000 | 0.0% | 1 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +14.1% | +14.8% | -0.7% | 100% |
| Q1 2026 | +0.9% | -4.6% | +5.5% | 100% |
| Q4 2025 | +5.1% | +2.4% | +2.7% | 100% |
| Q3 2025 | +21.5% | +7.8% | +13.7% | 100% |
| Q2 2025 | +12.5% | +10.5% | +2.0% | 100% |
| Q1 2025 | -9.9% | -4.6% | -5.3% | 100% |
| Q4 2024 | +7.3% | +2.1% | +5.2% | 100% |
| Q3 2024 | +11.0% | +5.4% | +5.6% | 99% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $10.9B | 87 |
| Q1 2026 | $9.4B | 83 |
| Q4 2025 | $8.4B | 76 |
| Q3 2025 | $8.9B | 72 |
| Q2 2025 | $6.6B | 66 |
| Q1 2025 | $5.6B | 65 |
| Q4 2024 | $7.8B | 69 |
| Q3 2024 | $6.1B | 64 |
| Q2 2024 | $3.8B | 67 |
| Q1 2024 | $3.4B | 68 |
| Q4 2023 | $4.8B | 58 |
| Q3 2023 | $2.7B | 61 |